Literature DB >> 26295078

PCSK9 Inhibitors and Cardiovascular Events.

Marc S Sabatine, Scott M Wasserman, Evan A Stein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26295078     DOI： 10.1056/NEJMc1508222

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Statins and Their Effect on PCSK9-Impact and Clinical Relevance.

Authors:  Beth A Taylor; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

2.  Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis.

Authors:  Teresa Trenkwalder; Christopher P Nelson; Muntaser D Musameh; Ify R Mordi; Thorsten Kessler; Costanza Pellegrini; Radoslaw Debiec; Tobias Rheude; Viktor Lazovic; Lingyao Zeng; Andreas Martinsson; J Gustav Smith; Jesper R Gådin; Anders Franco-Cereceda; Per Eriksson; Jonas B Nielsen; Sarah E Graham; Cristen J Willer; Kristian Hveem; Adnan Kastrati; Peter S Braund; Colin N A Palmer; Amparo Aracil; Oliver Husser; Wolfgang Koenig; Heribert Schunkert; Chim C Lang; Christian Hengstenberg; Nilesh J Samani
Journal:  Int J Cardiol       Date:  2018-11-17       Impact factor: 4.164

3.  Association of Exome Sequences With Cardiovascular Traits Among Blacks in the Jackson Heart Study.

Authors:  Gina M Peloso; Leslie A Lange; Tibor V Varga; Deborah A Nickerson; Joshua D Smith; Michael E Griswold; Solomon Musani; Linda M Polfus; Hao Mei; Stacey Gabriel; Rakale Collins Quarells; David Altshuler; Eric Boerwinkle; Mark J Daly; Benjamin Neale; Adolfo Correa; Alex P Reiner; James G Wilson; Sekar Kathiresan
Journal:  Circ Cardiovasc Genet       Date:  2016-07-15

4.  Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.

Authors:  Charles J Glueck; Parth Shah; Naila Goldenberg; Marloe Prince; Kevin Lee; Vybhav Jetty; Ashwin Kumar; Michael Goldenberg; Ping Wang
Journal:  Lipids Health Dis       Date:  2016-03-12       Impact factor: 3.876

5.  Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.

Authors:  Parth Shah; Charles J Glueck; Vybhav Jetty; Naila Goldenberg; Matan Rothschild; Rashid Riaz; Gregory Duhon; Ping Wang
Journal:  Lipids Health Dis       Date:  2016-08-18       Impact factor: 3.876

Review 6.  Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.

Authors:  Terrence L Trentman; Steven G Avey; Harish Ramakrishna
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Oct-Dec

7.  Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.

Authors:  Vybhav Jetty; Charles J Glueck; Kevin Lee; Naila Goldenberg; Marloe Prince; Ashwin Kumar; Michael Goldenberg; Ishan Anand; Ping Wang
Journal:  Vasc Health Risk Manag       Date:  2017-07-06

8.  Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.

Authors:  Joshua Choi; Amir M Khan; Michael Jarmin; Naila Goldenberg; Charles J Glueck; Ping Wang
Journal:  Lipids Health Dis       Date:  2017-07-24       Impact factor: 3.876

Review 9.  PCSK9 and Atherosclerosis - Lipids and Beyond.

Authors:  Michael D Shapiro; Sergio Fazio
Journal:  J Atheroscler Thromb       Date:  2017-03-09       Impact factor: 4.928

Review 10.  Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.

Authors:  Philip Sarges; Joshua M Steinberg; James H Lewis
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.228
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.